AR066564A1 - Una combinacion farmaceutica sinergica para el tratamiento de cancer - Google Patents

Una combinacion farmaceutica sinergica para el tratamiento de cancer

Info

Publication number
AR066564A1
AR066564A1 ARP080102040A ARP080102040A AR066564A1 AR 066564 A1 AR066564 A1 AR 066564A1 AR P080102040 A ARP080102040 A AR P080102040A AR P080102040 A ARP080102040 A AR P080102040A AR 066564 A1 AR066564 A1 AR 066564A1
Authority
AR
Argentina
Prior art keywords
cancer treatment
pharmaceutical combination
synergic
synergic pharmaceutical
combination
Prior art date
Application number
ARP080102040A
Other languages
English (en)
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of AR066564A1 publication Critical patent/AR066564A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP080102040A 2007-05-15 2008-05-14 Una combinacion farmaceutica sinergica para el tratamiento de cancer AR066564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2007/051841 WO2008139271A2 (en) 2007-05-15 2007-05-15 A synergistic pharmaceutical combination for the treatment of cancer

Publications (1)

Publication Number Publication Date
AR066564A1 true AR066564A1 (es) 2009-08-26

Family

ID=40002696

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102040A AR066564A1 (es) 2007-05-15 2008-05-14 Una combinacion farmaceutica sinergica para el tratamiento de cancer

Country Status (18)

Country Link
US (1) US8822526B2 (es)
EP (1) EP2154971B1 (es)
JP (1) JP5688288B2 (es)
KR (1) KR101403100B1 (es)
CN (1) CN101677567B (es)
AR (1) AR066564A1 (es)
AT (1) ATE538652T1 (es)
AU (1) AU2007353129B2 (es)
BR (1) BRPI0721626A2 (es)
CA (1) CA2687204C (es)
DK (1) DK2154971T3 (es)
ES (1) ES2380129T3 (es)
IL (1) IL202014A (es)
MX (1) MX2009012155A (es)
NZ (1) NZ581183A (es)
PT (1) PT2154971E (es)
TW (1) TWI449525B (es)
WO (1) WO2008139271A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
US20120009203A1 (en) * 2010-06-29 2012-01-12 Anahid Jewett Depletion of cancer stem cells
US9763982B2 (en) 2010-06-29 2017-09-19 The Regents Of The University Of California Depletion of cancer stem cells
RU2013127655A (ru) * 2010-11-19 2014-12-27 Пирамал Энтерпрайзис Лимитед Фармацевтическая комбинация паклитаксела и ингибитора cdk
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
BR112013033311A2 (pt) 2011-06-24 2017-08-22 Piramal Entpr Ltd Compostos para o tratamento de cânceres associados com papilomavírus humano
CA2917742C (en) 2013-07-12 2020-04-14 Piramal Enterprises Limited A pharmaceutical combination for the treatment of melanoma
CA2982928A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
KR102608921B1 (ko) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. 생체 이용률이 증가된 알보시딥 프로드러그
CN108289861B (zh) 2015-08-03 2021-11-02 大日本住友制药肿瘤公司 用于治疗癌症的组合疗法
KR102545392B1 (ko) 2016-03-28 2023-06-20 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11994511B2 (en) 2017-04-04 2024-05-28 University Of Miami Biomarkers indicative of prostate cancer and treatment thereof
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
US11510943B2 (en) * 2018-03-12 2022-11-29 Yeditepe Universitesi Chemotherapeutic agent comprising combination of alexidine dihydrochloride and sodium pentaborate pentahydrate
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
RU2710273C1 (ru) * 2019-04-24 2019-12-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Фармацевтическая композиция для лечения злокачественных новообразований
CN114767669B (zh) * 2022-05-20 2023-07-04 湖南省中医药研究院 一种P-gp抑制剂及其提取方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915301B2 (en) * 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) * 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
US7884127B2 (en) * 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
WO2004041308A1 (en) * 2002-11-06 2004-05-21 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
JP2007513202A (ja) * 2003-12-08 2007-05-24 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ 相乗的な抗癌組成物
WO2006099193A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof

Also Published As

Publication number Publication date
US20100305057A1 (en) 2010-12-02
WO2008139271A2 (en) 2008-11-20
EP2154971A4 (en) 2010-05-19
CA2687204A1 (en) 2008-11-20
EP2154971B1 (en) 2011-12-28
JP5688288B2 (ja) 2015-03-25
KR101403100B1 (ko) 2014-06-19
CN101677567A (zh) 2010-03-24
AU2007353129A1 (en) 2008-11-20
CA2687204C (en) 2015-11-24
PT2154971E (pt) 2012-04-10
AU2007353129B2 (en) 2014-02-20
KR20100017763A (ko) 2010-02-16
DK2154971T3 (da) 2012-04-02
ATE538652T1 (de) 2012-01-15
ES2380129T3 (es) 2012-05-08
IL202014A0 (en) 2010-06-16
EP2154971A2 (en) 2010-02-24
JP2010526862A (ja) 2010-08-05
WO2008139271A3 (en) 2009-04-23
TW200913991A (en) 2009-04-01
IL202014A (en) 2014-06-30
NZ581183A (en) 2012-03-30
MX2009012155A (es) 2010-01-15
US8822526B2 (en) 2014-09-02
TWI449525B (zh) 2014-08-21
CN101677567B (zh) 2013-06-19
BRPI0721626A2 (pt) 2013-01-22

Similar Documents

Publication Publication Date Title
AR066564A1 (es) Una combinacion farmaceutica sinergica para el tratamiento de cancer
LTPA2018005I1 (lt) Farmacinė kompozicija
BRPI0906467A2 (pt) forma de dose farmacêutica
DK2121139T3 (da) Formulations for cancer treatment
BRPI0920521A2 (pt) combinação farmacêutica
IT1394860B1 (it) Composti farmaceutici
BRPI0721651A2 (pt) Composição farmacêutica
PL2170275T3 (pl) Dwuczęściowa postać dawkowania w formie pastylki do ssania
BRPI0917549A2 (pt) dispositivo para a liberação de um medicamento
BRPI1008664A2 (pt) comprimidos para a terapia de combinação
BRPI0821129A2 (pt) Métodos para a inibição de cicatrização
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
ATE493119T1 (de) Pharmazeutische zusammensetzung
BRPI0913873A2 (pt) recipiente para dose única
BRPI0922884A2 (pt) compostos para tratamento de câncer
EP2170303A4 (en) DOSAGE FORMS MARKED BY LASER
ZA200903858B (en) Pharmaceutical dosage form
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0807882A2 (pt) Forma de dosagem
IT1393930B1 (it) Composti farmaceutici
BRPI0818598A2 (pt) agentes terapêuticos - 802
EP2145884A4 (en) INDOLEDIONDERIVAT
BRPI0920522A2 (pt) embalagem para administração de fármaco iontoforético

Legal Events

Date Code Title Description
FB Suspension of granting procedure